Sirolimus
- Generic Name
- Sirolimus
- Brand Names
- Fyarro, Hyftor, Rapamune
- Drug Type
- Small Molecule
- Chemical Formula
- C51H79NO13
- CAS Number
- 53123-88-9
- Unique Ingredient Identifier
- W36ZG6FT64
- Background
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria Streptomyces hygroscopicus, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive a...
- Indication
Sirolimus is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants. In patients at low-to moderate-immunologic risk, it is recommended that sirolimus be used initially in a regimen with cyclosporine and corticosteroids; cyclosporine should be withdrawn two to four months after transplantation. In pati...
- Associated Conditions
- Chordomas, Facial Angiofibroma, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Lymphangioleiomyomatosis (LAM), Renal Angiomyolipomas, Transplanted Organ Rejection, Metastatic malignant Perivascular Epithelioid Cell Neoplasms, Unresectable, locally advanced malignant Perivascular Epithelioid Cell Neoplasms
- Associated Therapies
- -
Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-04-16
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Emory University
- Target Recruit Count
- 3
- Registration Number
- NCT04348292
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia
- First Posted Date
- 2020-04-10
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 32
- Registration Number
- NCT04341675
- Locations
- 🇺🇸
Loyola University Medical Center, Chicago, Illinois, United States
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 59
- Registration Number
- NCT04339101
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Cemiplimab in AlloSCT/SOT Recipients With CSCC
- Conditions
- Interventions
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT04339062
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 36
- Registration Number
- NCT04177004
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Enhancing Self Regulation Among Smokers
- Conditions
- Interventions
- First Posted Date
- 2019-11-13
- Last Posted Date
- 2021-03-09
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 22
- Registration Number
- NCT04161144
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms
- Conditions
- Interventions
- First Posted Date
- 2019-10-28
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 80
- Registration Number
- NCT04141020
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)
- Conditions
- Interventions
- First Posted Date
- 2019-10-15
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Prevail Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT04127578
- Locations
- 🇺🇸
Rocky Mountain Clinical Research - CenExel - PPDS, 701 East Hampden Avenue Suite 510, Englewood, Colorado, United States
🇺🇸Northwestern University Feinberg School of Medicine, Dept. of Neurology, Parkinson's Disease & Movement Disorders Center, 710 N. Lake Shore Drive, 11th Floor, Chicago, Illinois, United States
🇮🇱Tel Aviv Sourasky Medical Center, 6 Weizmann St., Tel Aviv, Israel
Sirolimus for Cowden Syndrome With Colon Polyposis
- Conditions
- Interventions
- First Posted Date
- 2019-09-19
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Ohio State University
- Target Recruit Count
- 10
- Registration Number
- NCT04094675
- Locations
- 🇺🇸
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases
- Conditions
- Interventions
- Biological: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10Drug: FludarabineDrug: CyclophosphamideBiological: Lapine T-Lymphocyte Immune GlobulinRadiation: Total-Body IrradiationProcedure: Hematopoietic Cell TransplantationDrug: Mycophenolate MofetilDrug: SirolimusProcedure: Bone Marrow AspirationProcedure: Biospecimen Collection
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT04083183
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.